NIMENRIX

(meningococcal group ACWY polysaccharide conjugate vaccine adsorbed)

Find NIMENRIX medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

NIMENRIX Quick Finder

The Nimenrix Summary of Product Characteristics (SmPC) is available here.

Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal disease caused by Neisseria meningitidis groups A, C, W-135, and Y.

Nimenrix should be used in accordance with available official recommendations.

Didn’t find what you were looking for?

Contact us

Call 01 58 07 34 40*

*Contact Medical Information. 09h - 18h Monday to Friday.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to a Pfizer product, click on the link:
www.pfizersafetyreporting.com
If you cannot use the above website, please contact Pfizer pharmacovigilance at FRA.AEReporting@pfizer.com.

Governmental website

You may also report adverse events online on the Ministry of Health’s website ‘Portail de signalement des événements sanitaires indésirables’ at https://signalement.social-sante.gouv.fr